Trial document



drksid header

  DRKS00025271

Trial Description

start of 1:1-Block title

Title

Evaluation of immunogenicity and reactogenicity of heterologous covid-19 vaccine combination ChAdOx-1S followed by BNT162b2

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

Covid vaccine combination AstraZeneca and Biontech

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Antibody response before and after booster immunization with vaccine from Biontech after vaccination with vaccine from Astrazeneca will be evaluated. Also antibody titers will be compared with titers from vaccinees who received the Biontech vaccine twice. Further on, reactogenicity of both shots in this combination will be evaluated.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Antibody response before and after booster immunization with vaccine from Biontech after vaccination with vaccine from Astrazeneca will be evaluated. Antibody titers will be compared with titers from vaccinees who received the Biontech vaccine twice. Furtheron, reactogenicity of both shots in this combination will be evaluated.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

No

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

There won't be many data which exceed those which will be published.

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00025271
  •   2021/05/11
  •   [---]*
  •   yes
  •   Approved
  •   21-2374-101, Ethikkommission an der Universität Regensburg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   prevention covid
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   The intervention is two blood draws. One before and one after the decond vaccination in order to evaluate the effect of the vaccination.
    The vaccination as such is recommended and thus not part of the study.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Prevention
  •   Single (group)
  •   IV
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Blood draws before and 4(-6) weeks after the second vaccination with determination of anti-SARS-Cov-2-antiodies in serum by ELISA.
A questionnaire will be handed out and collected at date of second blood draw. Side effects of first and second dose will be asked for.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Comparison of antibody titers with those of vaccinees of another study who received the Biontech vaccine twice

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Planned
  •   2021/05/19
  •   154
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   60   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

There had been vaccinated 154 HCW of the university clinics of Regensburg an March 15, 2021 with the Astrazeneca vaccine. Everyone who wants to receive the second dose with the vaccine from Biontech is offered the participation in the study.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

First Covid vaccination not with Astrazeneca. contraindication to vaccination with biontech vaccine

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Uniklinik Regensburg Abteilung für Hygiene und Infektiologie
    • Ms.  Dr. med  Stilla  Bauernfeind 
    • F.-J.-Struß-Allee 11
    • 93053  Regensburg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • Institut für Klinische Mikrobiologie Abteilung für Virologie
    • Ms.  PD Dr. med.  Annelie  Plentz 
    • F.-J.-Strauß-Allee 11
    • 93053  Regensburg
    • Germany
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Uniklinik Regensburg Abteilung für Hygiene und Infektiologie
    • Ms.  Dr. med  Stilla  Bauernfeind 
    • F.-J.-Strauß-Allee 11
    • 93053  Regensburg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Uniklinik Regensburg Abteilung für Hygiene und Infektiologie
    • Ms.  Dr. med  Stilla  Bauernfeind 
    • F.-J.-Struß-Allee 11
    • 93053  Regensburg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Institut für Klinische Mikrobiologie Abteilung für Virologie
    • Ms.  PD Dr. med.  Annelie  Plentz 
    • F.-J.-Strauß-Allee 11
    • 93053  Regensburg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.